143 related articles for article (PubMed ID: 11606139)
1. Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole analogues as novel antiplatelet agents.
Lee FY; Lien JC; Huang LJ; Huang TM; Tsai SC; Teng CM; Wu CC; Cheng FC; Kuo SC
J Med Chem; 2001 Oct; 44(22):3746-9. PubMed ID: 11606139
[TBL] [Abstract][Full Text] [Related]
2. The design and synthesis of YC-1 analogues as probes for soluble guanylate cyclase.
Hering KW; Artz JD; Pearson WH; Marletta MA
Bioorg Med Chem Lett; 2006 Feb; 16(3):618-21. PubMed ID: 16326101
[TBL] [Abstract][Full Text] [Related]
3. New antithrombotics with an indazole structure.
Yildiz AK; Rehse K; Stasch JP; Bischoff E
Arch Pharm (Weinheim); 2004 Jun; 337(6):311-6. PubMed ID: 15188220
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of a phosphonate analogue of the soluble guanylate cyclase activator YC-1.
Martin NI; Derbyshire ER; Marletta MA
Bioorg Med Chem Lett; 2007 Sep; 17(17):4938-41. PubMed ID: 17587571
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase.
Selwood DL; Brummell DG; Budworth J; Burtin GE; Campbell RO; Chana SS; Charles IG; Fernandez PA; Glen RC; Goggin MC; Hobbs AJ; Kling MR; Liu Q; Madge DJ; Meillerais S; Powell KL; Reynolds K; Spacey GD; Stables JN; Tatlock MA; Wheeler KA; Wishart G; Woo CK
J Med Chem; 2001 Jan; 44(1):78-93. PubMed ID: 11141091
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272.
Mullershausen F; Russwurm M; Friebe A; Koesling D
Circulation; 2004 Apr; 109(14):1711-3. PubMed ID: 15066950
[TBL] [Abstract][Full Text] [Related]
7. YC-1 potentiates the antiplatelet effect of hydrogen peroxide via sensitization of soluble guanylate cyclase.
Wu CC; Kuo SC; Lee FY; Teng CM
Eur J Pharmacol; 1999 Sep; 381(2-3):185-91. PubMed ID: 10554886
[TBL] [Abstract][Full Text] [Related]
8. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
[TBL] [Abstract][Full Text] [Related]
9. Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway.
Hwang TL; Hung HW; Kao SH; Teng CM; Wu CC; Cheng SJ
Mol Pharmacol; 2003 Dec; 64(6):1419-27. PubMed ID: 14645672
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of extracellular Ca(2+) entry by YC-1, an activator of soluble guanylyl cyclase, through a cyclic GMP-independent pathway in rat neutrophils.
Wang JP; Chang LC; Huang LJ; Kuo SC
Biochem Pharmacol; 2001 Sep; 62(6):679-84. PubMed ID: 11551512
[TBL] [Abstract][Full Text] [Related]
11. Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat.
Wegener JW; Gath I; Förstermann U; Nawrath H
Br J Pharmacol; 1997 Dec; 122(7):1523-9. PubMed ID: 9421305
[TBL] [Abstract][Full Text] [Related]
12. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of the nitric oxide receptor, soluble guanylyl cyclase, in cerebellar cells.
Bellamy TC; Garthwaite J
Br J Pharmacol; 2002 May; 136(1):95-103. PubMed ID: 11976273
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of tumor necrosis factor-alpha expression by YC-1 in alveolar macrophages through a cyclic GMP-independent pathway.
Hwang TL; Wu CC; Guh JH; Teng CM
Biochem Pharmacol; 2003 Jul; 66(1):149-56. PubMed ID: 12818375
[TBL] [Abstract][Full Text] [Related]
15. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.
Mülsch A; Bauersachs J; Schäfer A; Stasch JP; Kast R; Busse R
Br J Pharmacol; 1997 Feb; 120(4):681-9. PubMed ID: 9051308
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the vasorelaxant effects of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1) and diethylamine/nitric oxide (DEA/NO) on the human radial artery used as coronary bypass graft.
Berkan O; Bagcivan I; Kaya T; Yildirim K; Yildirim S; Doğan K
Can J Physiol Pharmacol; 2007 May; 85(5):521-6. PubMed ID: 17632587
[TBL] [Abstract][Full Text] [Related]
17. 1-Benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (YC-1) derivatives as novel inhibitors against sodium nitroprusside-induced apoptosis.
Lien JC; Lee FY; Huang LJ; Pan SL; Guh JH; Teng CM; Kuo SC
J Med Chem; 2002 Nov; 45(23):4947-9. PubMed ID: 12408703
[TBL] [Abstract][Full Text] [Related]
18. An evolutionarily conserved mechanism for sensitization of soluble guanylyl cyclase reveals extensive nitric oxide-mediated upregulation of cyclic GMP in insect brain.
Ott SR; Delago A; Elphick MR
Eur J Neurosci; 2004 Sep; 20(5):1231-44. PubMed ID: 15341595
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole.
Chien WL; Liang KC; Teng CM; Kuo SC; Lee FY; Fu WM
Mol Pharmacol; 2003 Jun; 63(6):1322-8. PubMed ID: 12761342
[TBL] [Abstract][Full Text] [Related]
20. Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents.
Liu S; Li S; Yuan D; Wang E; Xie R; Zhang W; Kong Y; Zhu X
Eur J Med Chem; 2021 Jan; 209():112893. PubMed ID: 33049608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
